You are here

Minimal Residual Disease

sandy craine's picture
Submitted by sandy craine on Thu, 10/05/2012 - 12:56pm
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1 Abstract: Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1

Abstract:
Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

sandy craine's picture
Submitted by sandy craine on Sat, 10/03/2012 - 11:51am

Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

sandy craine's picture
Submitted by sandy craine on Sun, 05/02/2012 - 12:41pm

 

Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.

 

Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Mon, 30/01/2012 - 4:46pm

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.  Jorge Cortes, January 2012

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.  Jorge Cortes, January 2012

Pages